Navigation Links
Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
Date:6/14/2010

ermine what, if any, impact these data might have on other ongoing clinical trials evaluating the safety and efficacy of Nexavar.

"Bayer and Onyx are disappointed with these results, in particular, for patients who are suffering from this deadly disease," said Dr. Dimitris Voliotis, Vice President, Global Clinical Development Oncology, Bayer HealthCare.  "We are confident in our clinical trial program exploring Nexavar's potential in a variety of tumor types, including lung cancer.  Based on encouraging data from a recently presented prospective biomarker trial and Phase 2 signal-generating lung cancer studies, we believe it's critical to continue our evaluation of Nexavar in combination with targeted agents and as a monotherapy in later lines of treatment in lung cancer patients."

Nexavar is being evaluated by the companies and individual investigators in a variety of treatment settings for patients with non-small cell lung cancer, including a Phase 3 monotherapy study in the third- and fourth-line setting and Phase 2 studies in combination with other therapies in the second-line setting.

NExUS Trial Design

This Phase 3, randomized, double-blind, placebo-controlled study evaluated Nexavar (sorafenib) tablets in combination with the chemotherapeutic agents, gemcitabine and cisplatin, in treatment-naive non-small cell lung cancer patients.  The primary endpoint was overall survival, and secondary endpoints included progression-free survival, tumor response and safety.  Patients were randomized to receive 400 mg of oral Nexavar or matching placebo twice daily, in addition to gemcitabine and cisplatin for up to six cycles.  Subsequently, patients continued in a maintenance phase where Nexavar or placebo was administered as a single agent.  The study enrolled approximately 90
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Poniard Announces Final Data from Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
2. Onyx Pharmaceuticals Presents Interim Results of Phase 1b Carfilzomib Combination Trial
3. Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors
4. NeuroDerm Successfully Completes Enrollment and Dosing in a Phase 1 Clinical Study of ND0611 Dermal Patch for Parkinsons Disease
5. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
6. Bayer HealthCare Pharmaceuticals, Inc. Announces Results of a Phase 3 Clinical Trial of Gadobutrol
7. Mpex Pharmaceuticals Presents Positive Phase 2 Clinical Trial Results of Aeroquin(TM) (MP-376) Treatment in Cystic Fibrosis Patients
8. CrystalGenomics Announces Successful Completion of a Phase I SAD Clinical Trial for CG400549, its Novel Antibiotic Candidate
9. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
10. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
11. SARcode Corporation Announces Phase 2 Study Results of SAR 1118 Topical Ophthalmic Solution for the Treatment of Dry Eye
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013 Fuse Science, Inc. (OTCQB: ... company that is developing new, patent-pending technologies poised to redefine ... that it will hold a business update teleconference and webcast ... nd , 2013 at 4:30 PM ET. ... will host the call and will be joined by ...
(Date:5/17/2013)... May 17, 2013  Atossa Genetics, Inc. (NASDAQ: ... Kyle Guse , Chief Financial Officer & General ... Conference on Thursday, May 30, 2013, in New ... The Company,s presentation is scheduled to begin at ... webcast. To access the webcast, go to www.atossagenetics.com . ...
(Date:5/17/2013)... 2013 Sinovac Biotech Ltd. (Nasdaq: SVA ... , today announced that it will release its unaudited ... before market on Tuesday, May 28, 2013.  The Company will ... 8:00 a.m. EDT (May 28, 2013 at 8:00 p.m. China ... an update on recent corporate developments. To access ...
Breaking Medicine Technology:Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 2Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 3Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 2Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 3
(Date:5/18/2013)... In a May 14, 2013 article entitled ... Discovering Cancer Gene,” Fox News reported the movie star ... she carried a gene that doctors estimated gave her ... 50 percent risk of ovarian cancer (go to: goo.gl/5JHBP). ... 2013 with a blog post entitled “A Patient’s Journey: ...
(Date:5/18/2013)... Springs, FL (PRWEB) May 18, 2013 The ... dedicated to the special places we call home. These are ... on maps. They are the locations where the people are ... first-rate show takes viewers off the highways and shares the ... best of both nations with an American sports and film ...
(Date:5/18/2013)... Family Magazine of Washington DC was awarded the ... Consulting, Inc. in the category of Summer Camps in ... of the areas best in the ultimate guide on parenting, ... than Brenda Hyde, a mother of four and publisher of ... the vast resources available to them in the DC Metro ...
(Date:5/18/2013)... 2013 The “Sleep Apnea Diagnostic & ... Masks, Adaptive Servo-Ventilation (ASV), Oral Appliances, Nasal EPAP, Neurostimulation] ... analyzes and studies the major market drivers, restraints, and ... the World. , Browse , ... Figures , 318 pagesand in-depth TOC ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 The California ... 2013 therapies. At the Ayurvedic Spa , the ... panchakarma practitioner and lifestyle recommendations and stress ... “knowledge of life", is the traditional healthcare system of ... life of harmony is the basis for all optimum ...
Breaking Medicine News(10 mins):Health News:Angelina Jolie – Scarless Breast Augmentation Surgery 2Health News:Communities of Distinction TV Presents "A Place to Call Home" Segment 2Health News:Summer Camps in DC "Best of the Best" Awarded to Family Magazine of Washington DC for Excellence by Follow Media Consulting, Inc. 2Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 2Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 3Health News:Ayurveda Spa Treatments Now Offered at the California College of Ayurveda Panchakarma Center 2
... The supervisory board of Celesio AG has today approved ... wholesaler Panpharma. This step into one of the most ... Celesio,s growth strategy. Celesio doesn,t plan to setup a ... about two years thoroughly analysing the Brazilian pharmaceutical market, ...
... mental stress not seen in those with high blood pressure, ... and other forms of mental stress cause dilation of the ... brain in healthy people, but this doesn,t occur in those ... researchers who used ultrasound imaging to monitor the carotid arteries ...
... , SACRAMENTO, Calif., July 10 After several months ... the chief executive officer of a leading statewide mental ... shop Psycho Donuts, will meet face to face to ... questionable business practices. , , Owners Kipp Berdiansky ...
... Aegis of Granada Hills has been named "Best Assisted Living ... their annual Readers Choice Awards. This is the second year in ... award. In voting, Aegis was a write-in candidate and received ... metro area to gain top status. , , ...
... 10 A sometimes fatal "superbug" is popping up in ... people live. It,s called methicillin-resistant Staphylococcus aureus, (MRSA "mer,-sa"). Health ... to slow its spread. , , "Physicians, health ... threat through the appropriate use of antibiotics, proper wound care ...
... more than half of patients reported improvement , FRIDAY, July ... asthma and other respiratory conditions shows promise in restoring a ... ability. , "More work needs to be done but, for ... an option worth trying," said Dr. Ronald Kuppersmith, clinical assistant ...
Cached Medicine News:Health News:Celesio Acquires Majority Stake in Number One Brazilian Pharmaceutical Wholesaler Panpharma 2Health News:Blood Rush to the Brain When Angry Is a Good Sign 2Health News:There Is No Way to Sugar Coat These Donuts 2Health News:Blue Cross and Blue Shield of Illinois Urges Constant Vigilance Against Growing Threat of Killer 'Superbug' 2Health News:Blue Cross and Blue Shield of Illinois Urges Constant Vigilance Against Growing Threat of Killer 'Superbug' 3Health News:Drug Might Restore Sense of Smell 2Health News:Drug Might Restore Sense of Smell 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: